BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic … Read more
BGI Genomics Co Ltd (300676) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.93 Billion CNY
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has total liabilities worth CN¥2.93 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BGI Genomics Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how BGI Genomics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BGI Genomics Co Ltd Competitors by Total Liabilities
The table below lists competitors of BGI Genomics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianma Microelectronics Co Ltd
SHE:000050
|
China | CN¥47.49 Billion |
|
Dalrymple Bay Infrastructure Ltd
AU:DBI
|
Australia | AU$2.51 Billion |
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
Canada | CA$2.75 Billion |
|
Motor Oil (Hellas) Corinth Refineries S.A
PINK:MOHCF
|
USA | $4.71 Billion |
|
Intuitive Machines Inc.
NASDAQ:LUNR
|
USA | $509.70 Million |
|
Century Communities Inc
NYSE:CCS
|
USA | $1.89 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down BGI Genomics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BGI Genomics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BGI Genomics Co Ltd (2012–2024)
The table below shows the annual total liabilities of BGI Genomics Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.27 Billion | -9.37% |
| 2023-12-31 | CN¥3.61 Billion | -13.08% |
| 2022-12-31 | CN¥4.15 Billion | -13.73% |
| 2021-12-31 | CN¥4.81 Billion | -6.90% |
| 2020-12-31 | CN¥5.17 Billion | +242.77% |
| 2019-12-31 | CN¥1.51 Billion | +50.95% |
| 2018-12-31 | CN¥999.04 Million | +17.00% |
| 2017-12-31 | CN¥853.88 Million | +9.82% |
| 2016-12-31 | CN¥777.52 Million | +4.88% |
| 2015-12-31 | CN¥741.37 Million | +27.08% |
| 2014-12-31 | CN¥583.40 Million | -35.14% |
| 2013-12-31 | CN¥899.46 Million | +5.41% |
| 2012-12-31 | CN¥853.31 Million | -- |